Senior Biostatistician

ImmunityBio is a clinical-stage biotechnology company developing next-generation immunotherapies and cell therapies that strengthen the immune system to treat cancer and infectious diseases.

ImmunityBio, Inc.

Salary: 144k-180k USD

United States only

Stay safe on Himalayas

Never send money to companies. Jobs on Himalayas will never require payment from applicants.

ImmunityBio, Inc. is seeking a Senior Biostatistician to lead the design, management, and technical oversight of statistical analyses and reporting of clinical trial data. The role involves leading clinical trials, developing statistical analysis plans, and providing analytical insights to internal teams. The ideal candidate will have a strong background in biostatistics and experience in the biotech or pharmaceutical industry.

Requirements

Bachelor's or Master's degree in Statistics or Biostatistics
7+ years of relevant experience in biostatistics, with at least 3 years in a lead role
Experience in CDISC STDM/ADaM, SAS, and sample size software
Excellent communication and organizational skills

Benefits

Medical, Dental, and Vision Plan Options
Health and Financial Wellness Programs
Employer Assistance Program (EAP)
Company Paid and Voluntary Life/AD&D, Short-Term and Long-Term Disability
Healthcare and Dependent Care Flexible Spending Accounts
401(k) Retirement Plan with Company Match
529 Education Savings Program
Voluntary Legal Services, Identity Theft Protection, Pet Insurance and Employee Discounts, Rewards and Perks
Paid Time Off (PTO)

Apply now

Please let ImmunityBio, Inc. know you found this job on Himalayas. This helps us grow!

Apply now

About the job

Apply before

May 23, 2026

Posted on

Mar 24, 2026

Job type

Full Time

Experience level

Senior

Salary

Salary: 144k-180k USD

Location requirements

United States

Hiring timezones

United States +/- 0 hours

About ImmunityBio, Inc.

Learn more about ImmunityBio, Inc. and their company culture.

View company profile

At ImmunityBio, we're driven by a patient-first culture that guides everything we do. Our team of scientists, doctors, and staff work tirelessly to transform living biological technologies into innovative treatments for cancer and infectious diseases. We believe in empowering the body's own immune system - rather than weakening it - by developing therapies that activate both innate and adaptive immune responses to create durable, complete responses.

Our scientific approach centers on a proprietary natural killer cell platform that can be expanded, genetically modified, and cryopreserved. With 27 clinical trials across 13 indications, our lead product ANKTIVA® (N-803) has earned FDA Breakthrough Therapy designation for BCG-unresponsive non-muscle invasive bladder cancer. Founded by Dr. Patrick Soon-Shiong in 2014, we've grown into a clinical-stage biotechnology company with deep expertise in genomics, proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapies. Our success is measured not by milestones, but by the quality of life we can offer patients who need these therapies most.